New Approach to Hep C
University of New South Wales, Australia28th September 2010
Genetic fingerprinting may predict who will benefit from early hepatitis C treatment and who will clear the virus spontaneously, new research shows.
The way doctors think about hepatitis C treatment is changing, with researchers saying it is now possible to use genotyping to predict which patients are likely to clear the infection spontaneously and which will benefit from early therapy.
A team of UNSW researchers, led by Professor Gregory Dore and Dr Jason Grebely, has determined that genetic changes near the human IL28B gene – identified recently as linked to the ability to control hepatitis C infection – may also be used to identify those patients with recent infection whose own immune system is likely to clear the virus without therapy.
“The use of human genotyping may change the landscape of how we treat patients with recent HCV infection,” said Dr Grebely, a lecturer in the Viral Hepatitis and Clinical Research Program at UNSW’s National Centre in HIV Epidemiology and Clinical Research (NCHECR).
It’s the first time that patients with early hepatitis C infection, who are likely to clear the virus on their own, might be identified and spared treatment, which is expensive and has side effects, Dr Grebely said.
“IL28B genetic testing, prior to treatment for HCV infection, is likely to be incorporated into clinical care to identify those most likely to respond,” Dr Grebely said. “For those patients without the favourable genotype, the doctor can proceed with treatment, knowing it is better to treat early than waiting until the condition has become chronic.”
The findings, to be published this week in the journal Hepatology, are a collaboration between researchers at NCHECR; the Burnet Institute; The Alfred Hospital, Melbourne; St Vincent’s Hospital, Sydney; Westmead Millennium Institute and Westmead Hospital; University of Sydney; UNSW’s School of Medical Sciences and the Prince of Wales Hospital.
Media contacts: Dr Jason Grebely and Professor Greg Dore, NCHECR | 9385 0900 |
The way doctors think about hepatitis C treatment is changing, with researchers saying it is now possible to use genotyping to predict which patients are likely to clear the infection spontaneously and which will benefit from early therapy.
A team of UNSW researchers, led by Professor Gregory Dore and Dr Jason Grebely, has determined that genetic changes near the human IL28B gene – identified recently as linked to the ability to control hepatitis C infection – may also be used to identify those patients with recent infection whose own immune system is likely to clear the virus without therapy.
“The use of human genotyping may change the landscape of how we treat patients with recent HCV infection,” said Dr Grebely, a lecturer in the Viral Hepatitis and Clinical Research Program at UNSW’s National Centre in HIV Epidemiology and Clinical Research (NCHECR).
It’s the first time that patients with early hepatitis C infection, who are likely to clear the virus on their own, might be identified and spared treatment, which is expensive and has side effects, Dr Grebely said.
“IL28B genetic testing, prior to treatment for HCV infection, is likely to be incorporated into clinical care to identify those most likely to respond,” Dr Grebely said. “For those patients without the favourable genotype, the doctor can proceed with treatment, knowing it is better to treat early than waiting until the condition has become chronic.”
The findings, to be published this week in the journal Hepatology, are a collaboration between researchers at NCHECR; the Burnet Institute; The Alfred Hospital, Melbourne; St Vincent’s Hospital, Sydney; Westmead Millennium Institute and Westmead Hospital; University of Sydney; UNSW’s School of Medical Sciences and the Prince of Wales Hospital.
Media contacts: Dr Jason Grebely and Professor Greg Dore, NCHECR | 9385 0900 |
No comments:
Post a Comment